Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
J Cardiovasc Pharmacol ; 31(4): 585-94, 1998 Apr.
Article in English | MEDLINE | ID: mdl-9554809

ABSTRACT

In end-stage heart failure, cardiac beta-adrenoceptors are decreased and cardiac Gi protein is increased. We assessed beta-adrenoceptors, G proteins, and effects of several beta-adrenoceptor agonists, histamine, and 5-HT on adenylyl cyclase activity in right and left atria and left ventricles and on left ventricular contractility in six potential heart transplant donors (nonfailing hearts; NFHs) and in nine patients with end-stage dilated cardiomyopathy (DCM) and 11 patients with end-stage ischemic cardiomyopathy (ICM) to establish whether the functional responsiveness of all cardiac Gs-coupled receptors is reduced. Beta-adrenoceptors were reduced in all three tissues; in DCM, beta1-adrenoceptors were more markedly downregulated; in ICM, both beta1- and beta2-adrenoceptors were diminished. In all three tissues, isoprenaline-, terbutaline-, histamine- and 5-HT-induced adenylyl cyclase activation was reduced similarly in DCM and ICM. Moreover, in DCM and ICM, guanosine triphosphate (GTP)- (involving Gs and Gi) activated adenylyl cyclase was significantly diminished, whereas NaF-activated (involving only Gs) and Mn2+-activated (acting at the catalytic unit of the enzyme) adenylyl cyclase was unaltered. Left ventricular positive inotropic responses to beta1- (noradrenaline, dopamine, and dobutamine), beta2- (terbutaline), and beta1- and beta2-adrenoceptors (isoprenaline, adrenaline, and epinine), as well as H2-receptor (histamine) stimulation were significantly reduced. The extent of reduction was not different for each agonist in ICM and DCM. We conclude that in DCM and ICM, functional responsiveness of all cardiac Gs-coupled receptors is similarly reduced.


Subject(s)
Cardiomyopathy, Dilated/metabolism , GTP-Binding Proteins/metabolism , Myocardial Ischemia/metabolism , Receptors, Adrenergic, beta/metabolism , Adenylyl Cyclases/analysis , Adenylyl Cyclases/metabolism , Adrenergic beta-Agonists/pharmacology , Adult , Cardiomyopathy, Dilated/physiopathology , Female , Guanosine Triphosphate/analysis , Guanosine Triphosphate/metabolism , Heart Atria/drug effects , Heart Atria/metabolism , Heart Transplantation , Heart Ventricles/drug effects , Heart Ventricles/metabolism , Histamine/pharmacology , Humans , Iodocyanopindolol , Male , Middle Aged , Myocardial Contraction/drug effects , Myocardial Ischemia/physiopathology , Pindolol/analogs & derivatives , Serotonin/pharmacology , Tissue Donors
2.
Naunyn Schmiedebergs Arch Pharmacol ; 347(4): 347-52, 1993 Apr.
Article in English | MEDLINE | ID: mdl-8389986

ABSTRACT

The receptor systems through which serotonin (5-HT), histamine, angiotensin II and endothelin increase the force of contraction were studied in isolated right atria from patients without apparent heart failure. All agonists increased the atrial force of contraction in a concentration-dependent manner; maximal effects, however, were significantly less than those evoked by isoprenaline or Ca2+. 5-HT and histamine, but not angiotensin II and endothelin, activated adenylate cyclase, whereas endothelin and angiotensin II stimulated inositol phosphate generation. Experiments with subtype-selective antagonists revealed that histamine effects were mediated by H2-receptors (sensitive to ranitidine), 5-HT-effects by 5-HT4-receptors (sensitive to SDZ 205-557) and angiotensin II effects by AT1-receptors (sensitive to losartan). We conclude that in human right atria the force of contraction can be increased by cyclic AMP-dependent (histamine, 5-HT) and -independent (angiotensin II, endothelin) pathways. Compared to beta-adrenoceptors, however, all other receptor systems increase the force of contraction only submaximally indicating that the beta-adrenoceptor pathway is the most important physiological mechanism to regulate force of contraction and/or heart rate in the human heart.


Subject(s)
Biological Factors/pharmacology , Myocardial Contraction/drug effects , Receptors, Cell Surface/drug effects , Adenylyl Cyclases/drug effects , Adult , Aged , Angiotensin II/pharmacology , Cardiotonic Agents/pharmacology , Dose-Response Relationship, Drug , Endothelins/pharmacology , Female , Heart Atria/drug effects , Histamine/pharmacology , Humans , In Vitro Techniques , Inositol Phosphates/metabolism , Isoproterenol/pharmacology , Male , Middle Aged , Myocardial Contraction/physiology , Receptors, Cell Surface/physiology , Serotonin/pharmacology , Stimulation, Chemical
3.
Circulation ; 87(2): 422-6, 1993 Feb.
Article in English | MEDLINE | ID: mdl-8381057

ABSTRACT

BACKGROUND: It is well known that during cardiopulmonary bypass (CPB) with cardioplegic cardiac arrest, catecholamines are vigorously increased. We therefore investigated whether this might cause desensitization of human cardiac beta-adrenoceptors. METHODS AND RESULTS: We assessed in 12 children with acyanotic congenital heart disease who underwent open-heart surgery right atrial beta-adrenoceptor number and subtype distribution [by (-)-[125I]iodocyanopindolol binding] and adenylate cyclase activation [by the beta-adrenoceptor agonist isoprenaline (100 microM) and by the non-receptor-mediated activators 10 microM GTP, 10 mM NaF, 100 microM forskolin, and 10 mM Mn2+] before and after CPB with cardiac arrest by means of St. Thomas' cardioplegic solution. CPB affected neither beta-adrenoceptor number of subtype distribution nor GTP-, NaF-, forskolin-, or Mn(2+)-induced activation of adenylate cyclase. In contrast, activation of adenylate cyclase by 100 microM isoprenaline was significantly (p = 0.0249) lower after CPB than before CPB. CONCLUSIONS: CPB with cardioplegic cardiac arrest decreases beta-adrenoceptor-mediated adenylate cyclase activation in a manner compatible with an uncoupling of beta-adrenoceptors from the Gs-protein-adenylate cyclase complex. Such a beta-adrenoceptor desensitization may be the reason why after CPB many patients need inotropic support but do not respond sufficiently to catecholamines.


Subject(s)
Cardiopulmonary Bypass , Heart Arrest, Induced , Myocardium/metabolism , Receptors, Adrenergic, beta/metabolism , Adenylyl Cyclases/metabolism , Adolescent , Child , Child, Preschool , Female , Humans , Infant , Intraoperative Period , Male
4.
Basic Res Cardiol ; 87 Suppl 1: 1-14, 1992.
Article in English | MEDLINE | ID: mdl-1353955

ABSTRACT

Catecholamines acting through beta 1- and beta 2-adrenoceptors cause positive inotropic and chronotropic effects in the human heart. In recent years, however, evidence has accumulated that in the human heart also other receptor systems can affect heart rate and/or contractility. Positive inotropic effects can be mediated by receptor systems acting through accumulation of intracellular cAMP (Gs-protein coupled receptors such as 5-HT4-like, histamine H2, and vasoactive intestinal peptide) or by receptor systems acting independent of cAMP possibly through the phospholipase C/diacylglycerol/inositol-1,4,5-trisphosphate pathway (such as alpha 1-adrenergic, angiotensin II, and endothelin). In the non-failing human heart, however, activation of all these receptor systems induces only submaximal positive inotropic effects when compared with those caused by beta-adrenoceptor stimulation, indicating that in humans the cardiac beta-adrenoceptor-Gs-protein-adenylate cyclase pathway is the most powerful mechanism to increase heart rate and contractility. On the other hand, at least three receptor systems acting through inhibition of cAMP formation (Gi-protein coupled receptors) exist in the human heart: muscarinic M2-, adenosine A1-, and somatostatin-receptors. Activation of M2- and A1-receptors causes negative inotropic effects in the non-failing human heart: in atria activation of both receptors causes decreases in basal as well as in isoprenaline-stimulated force of contraction, but in ventricles only isoprenaline-stimulated force of contraction is depressed.


Subject(s)
Heart/physiology , Myocardium/metabolism , Receptors, Adrenergic, beta/metabolism , Receptors, Muscarinic/metabolism , Adrenergic beta-Antagonists/pharmacology , Calcium/metabolism , GTP-Binding Proteins/metabolism , Humans , Receptors, Adrenergic, beta/drug effects , Signal Transduction
SELECTION OF CITATIONS
SEARCH DETAIL
...